Overview

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite treatment. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborator:
Gynecologic Oncology Group
Treatments:
Thalidomide